

BIOTIME INC  
Form 8-K  
July 17, 2012  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **July 17, 2012**

**BioTime, Inc.**

(Exact name of registrant as specified in its charter)

|  |                          |                                   |
|--|--------------------------|-----------------------------------|
| <b>California</b>                              | <b>1-12830</b>           | <b>94-3127919</b>                 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

**1301 Harbor Bay Parkway**  
**Alameda, California 94502**  
(Address of principal executive offices)

**(510) 521-3390**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

*Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions identify forward-looking statements.*

**Section 7 - Regulation FD**

**Item 7.01 - Regulation FD Disclosure**

On July 17, 2012, we announced agreements to provide Jade Therapeutics, LLC with our clinical grade *HyStem*<sup>®</sup> hydrogel product and related technology for use by Jade Therapeutics in the development of new pharmaceutical products for ophthalmologic use. Additional information can be found in the press release filed as Exhibit 99.1 and incorporated herein by reference.

**Section 9 - Financial Statements and Exhibits**

**Item 9.01 - Financial Statements and Exhibits.**

| <u>Exhibit Number</u> | <u>Description</u>                |
|-----------------------|-----------------------------------|
| 99.1                  | Press release dated July 17, 2012 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOTIME, INC.**

Date: July 17, 2012 By: /s/ Peter Garcia  
Chief Financial  
Officer

| <u>Exhibit Number</u> | <u>Description</u>                |
|-----------------------|-----------------------------------|
| 99.1                  | Press release dated July 17, 2012 |